Affiliation:
1. Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia, and the Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, Oxford University, Oxford, United Kingdom
Abstract
SUMMARY
The gravity of the threat posed by vivax malaria to public health has been poorly appreciated. The widely held misperception of
Plasmodium vivax
as being relatively infrequent, benign, and easily treated explains its nearly complete neglect across the range of biological and clinical research. Recent evidence suggests a far higher and more-severe disease burden imposed by increasingly drug-resistant parasites. The two frontline therapies against vivax malaria, chloroquine and primaquine, may be failing. Despite 60 years of nearly continuous use of these drugs, their respective mechanisms of activity, resistance, and toxicity remain unknown. Although standardized means of assessing therapeutic efficacy against blood and liver stages have not been developed, this review examines the provisional in vivo, ex vivo, and animal model systems for doing so. The rationale, design, and interpretation of clinical trials of therapies for vivax malaria are discussed in the context of the nuance and ambiguity imposed by the hypnozoite. Fielding new drug therapies against real-world vivax malaria may require a reworking of the strategic framework of drug development, namely, the conception, testing, and evaluation of sets of drugs designed for the cure of both blood and liver asexual stages as well as the sexual blood stages within a single therapeutic regimen.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Microbiology (medical),Public Health, Environmental and Occupational Health,General Immunology and Microbiology,Epidemiology
Reference241 articles.
1. Plasmodium vivax
Polymorphism in a Clinical Drug Trial
2. Akintowa, A., M. C. Meyer, and P. T. R. Hwang. 1983. Simultaneous determination of chloroquine and desethylchloroquine in blood, plasma, and urine by high-performance liquid chromatography. J. Liq. Chromatogr.6:1513-1522.
3. Alvarez, G., J.-G. Pineros, A. Tobon, A. Rios, A. Maestre, S. Blair, and J. C. Fonseca. 2006. Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia. Am. J. Trop. Med. Hyg.75:605-609.
4. Alving, A. S., T. N. Pullman, B. Craige, Jr., R. Jones, Jr., C. M. Whorton, and L. Eichelberger. 1948. The clinical trial of eighteen analogues of pamaquin (plamochin) in vivax malaria (Chesson strain). J. Clin. Lab. Investig.27(Suppl.):34-45.
5. Alving, A. S., D. D. Hankey, G. R. Coatney, R. Jones, Jr., W. G. Coker, P. L. Garrison, and W. N. Donovan. 1953. Korean vivax malaria. II. Curative treatment with pamaquine and primaquine. Am. J. Trop. Med. Hyg.2:970-976.
Cited by
226 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献